Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 6, 2025 in Altimmune Lawsuit – ALT GlobeNewswire August 08, 2025 NEW YORK, Aug. 08, 2025 (GLOBE NEWSWIRE) — Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT) of a class action securities lawsuit. CLASS DEFINITION: The […]

Fiserv, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before September 22, 2025 to Discuss Your Rights – FI GlobeNewswire August 08, 2025 NEW YORK, Aug. 08, 2025 (GLOBE NEWSWIRE) — Levi & Korsinsky, LLP notifies investors in Fiserv, Inc. (“Fiserv, Inc.” or the “Company”) (NYSE: FI) of a class

The John Hancock Closed-End Funds listed in the table below announced earnings1 for the three months ended July 31, 2025. The same data for the comparable three-month period ended July 31, 2024 is also available below. Three Months Ended 07/31/2025Ticker Fund Name Current Fiscal Net Investment Per Common NAV Total Managed Total Net Year End

The Board of Directors of Dover Corporation (NYSE: DOV) today increased its quarterly cash dividend to $0.52 (fifty-two cents) per share, from the previous $0.515 (fifty-one and one-half cents) per share, an increase of $0.005 (one-half cent). This is the 70th consecutive year in which the Company has increased its annual cash dividend, demonstrating Dover's

(NYSE:HIMS), NEW YORK, Aug. 08, 2025 (GLOBE NEWSWIRE) — Levi & Korsinsky, LLP notifies investors in Hims & Hers Health, Inc. (“Hims & Hers Health, Inc.” or the “Company”) (NYSE: HIMS) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Hims & Hers Health, Inc. investors who

(NYSE MKT:CLDI), Presented preclinical data at the American Society of Clinical Oncology (ASCO) on CLD-401 demonstrating biological efficacy IL-15 superagonist delivery to metastatic tumor sites and reduced immune clearance through engineered CD55 membrane expression; IND filing expected by the end of 2026 Received FDA Fast Track Designation for CLD-201, a first-in-class stem-cell loaded intratumoral viral

(NASDAQ:NODK), FARGO, N.D., Aug. 08, 2025 (GLOBE NEWSWIRE) — NI Holdings, Inc. (NASDAQ: NODK) announced today results for the quarter ended June 30, 2025. Summary of Second Quarter 2025 Results – Continuing Operations(All comparisons vs. continuing operations for the second quarter of 2024, unless noted otherwise) Direct written premiums of $109.5 million compared to $118.5

Investors in Hims & Hers Health, Inc. Should Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights – HIMS GlobeNewswire August 08, 2025 NEW YORK, Aug. 08, 2025 (GLOBE NEWSWIRE) — Levi & Korsinsky, LLP notifies investors in Hims & Hers Health, Inc. (“Hims & Hers Health, Inc.” or the “Company”) (NYSE:

Calidi Biotherapeutics Reports Second Quarter 2025 Financial Results and Recent Operational Highlights GlobeNewswire August 08, 2025 Presented preclinical data at the American Society of Clinical Oncology (ASCO) on CLD-401 demonstrating biological efficacy IL-15 superagonist delivery to metastatic tumor sites and reduced immune clearance through engineered CD55 membrane expression; IND filing expected by the end of

NI Holdings, Inc. Reports Results for Second Quarter Ended June 30, 2025 GlobeNewswire August 08, 2025 FARGO, N.D., Aug. 08, 2025 (GLOBE NEWSWIRE) — NI Holdings, Inc. (NASDAQ: NODK) announced today results for the quarter ended June 30, 2025. Summary of Second Quarter 2025 Results – Continuing Operations(All comparisons vs. continuing operations for the second